NEURACTHEL® manufacturing processes advance
CLINUVEL today announced an update on its commercial development of the analogue...
Read More
Media release: CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results from a clinical trial in a genetic DNA repair disorder show...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum - Technical Note
Melbourne, Australia, 16 January 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...
Read More
Afamelanotide Reduces DNA Photodamage in Xeroderma Pigmentosum
First Phase II results show decrease in UV-induced skin damage
Read More
CLINUVEL Communiqué VI
Melbourne, Australia, 23 December 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notification of cessation of securities
Melbourne, Australia, 21 December 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Jefferies London Healthcare Conference
CLINUVEL's Chief Executive Officer, Dr Philippe Wolgen, presents to the Jefferies Healthcare...
Read More
CLINUVEL Communiqué V
News Communiqué V discusses CLINUVEL's strong financial results in the face of...
Read More